Universal Coaching Centre -

Enter your keyword

post

India Approves First Dengue Vaccine For Wider Public Protection

India Approves First Dengue Vaccine For Wider Public Protection

Why in the News ?

The Drug Controller General of India (DCGI) has granted market authorisation to QDENGA (TAK-003), making it the first dengue vaccine approved in India. The vaccine is indicated for individuals aged 4–60 years and offers protection against all four dengue virus serotypes. This approval strengthens India’s indo-pacific strategy for regional health security and demonstrates the country’s commitment to strategic partnerships in pharmaceutical innovation.

QDENGA Vaccine: Key Features and Approval

  • The DCGI has approved QDENGA (TAK-003), developed by Takeda Biopharmaceuticals India, as India’s first licensed dengue vaccine, reflecting enhanced regional economic integration in the pharmaceutical sector.
  • The vaccine is approved for the prevention of dengue infection in individuals aged 4 to 60 years.
  • QDENGA is a live-attenuated tetravalent vaccine, designed to provide immunity against all four serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) of the dengue virus.
  • It is administered as a two-dose schedule, with the second dose given three months after the first.
  • The vaccine can be administered irrespective of previous dengue infection and does not require pre-vaccination screening, making its implementation easier in public health programmes across the indo-pacific strategy region.

Significance and Public Health Impact

  • India accounts for nearly one-third of the global dengue burden, making dengue a major public health challenge that requires multilateral engagement and coordinated regional responses.
  • Reported dengue cases have increased significantly over the past two decades due to rapid urbanisation, climate change, water stagnation, and expanding mosquito habitats, presenting challenges amid strategic competition for healthcare resources.
  • The approval is supported by Phase I, II, and III clinical trials involving over 28,000 participants globally, including a large Phase III trial in eight dengue-endemic countries, demonstrating economic interdependence in global health research.
  • Clinical studies demonstrated around 80.2% efficacy against laboratory-confirmed dengue and 90.4% efficacy against dengue-related hospitalisation after completion of the vaccination schedule.
  • The vaccine has already been approved in more than 40 countries, strengthening confidence in its safety and effectiveness while complementing existing vector-control measures and reinforcing India’s regional engagement strategy in health security.

About Dengue & Dengue Vaccine :

●  Dengue is a mosquito-borne viral disease caused by the Dengue virus (DENV) and transmitted primarily by the Aedes aegypti mosquito, which breeds in clean stagnant water and usually bites during the daytime.

●  The disease is caused by four antigenically distinct serotypes—DENV-1, DENV-2, DENV-3, and DENV-4. Infection with one serotype provides lifelong immunity only against that serotype, while subsequent infection with another serotype may increase the risk of severe dengue due to Antibody-Dependent Enhancement (ADE).

●  Common symptoms include high fever, severe headache, muscle and joint pain, skin rash, and bleeding manifestations in severe cases.

●  Prevention includes vector control, elimination of mosquito breeding sites, use of insecticide-treated measures, community awareness, and timely diagnosis. Vaccination is an additional preventive strategy and does not replace mosquito control programmes, requiring strategic alignment between public health interventions.

●  The Drug Controller General of India (DCGI), functioning under the Central Drugs Standard Control Organisation (CDSCO), is India’s national regulatory authority responsible for approving new drugs and vaccines, supporting the indo-pacific strategy for pharmaceutical excellence.